INTRODUCTION
Prostate cancer (PC) is the most common cancer in men in western Europe. In Sweden and Finland together, 15 000 new cases are diagnosed yearly. PC has evolved from being a cancer in which most patients have non-localized disease at diagnosis to a malignancy that, in the majority of the patients, is diagnosed when the tumor is still localized to the prostate. 1 This is due to earlier detection through PSA screening. Therefore, more patients undergo either radical prostatectomy or radical external-beam radiation in an attempt to cure the disease.
The TNM (T ¼ primary tumor, N ¼ regional lymph nodes, M ¼ distant metastasis) classification, Gleason grade and serum PSA all provide prognostic information for patients with PC receiving surgery or radiation. These parameters have been used to identify low-, intermediate-and high-risk patients. Before treatment, the risk of recurrence, metastasis and death from PC can be calculated based on serum PSA levels, T stage and Gleason score. 2--4 The localized high-risk group is defined as patients fulfilling one of the following criteria before surgery: PSA levels above 20 ng ml
À1
, Gleason grade 4 þ 3--10 and/or a T stage of T2c--T3b. 5, 6 Most patients are elderly men treated with curative radiotherapy. The patient prognosis depends on T stage, Gleason score, pretreatment PSA and radiation dose. 7 In a study by Shipley et al., 5-year biochemical failure-free survival rates after radical external radiotherapy in localized PC were 81% in patients with a pretreatment PSA of less than 10 ng ml
, 68% for those with a level of 10 to 20 ng ml À1 , 51% for those with a level of 20 to 30 ng ml À1 and only 31% for those with a level of 30 ng ml À1 or higher. In addition, by increasing the total radiation dose, biochemical failure-free survival has shown to improve. 9 The risk of metastasis after radiotherapy in intermediate-and high-risk patients is higher than that in the low-risk group, and the systemic treatment of potential micrometastases is a step toward improving metastases-free survival. Randomized trials have demonstrated the survival benefit of neoadjuvant and adjuvant hormonal treatment in locally advanced PC patients treated with radiotherapy. 10--16 Even short-term androgen deprivation (6 months) for patients with locally advanced PC significantly improved local failure rates (HR 0.42 (0.28--0.62), Po0.0001), biochemical failure-free survival (0.58 (0.46--0.74), Po0.0001), disease-free survival (0.56 (0.45--0.69), Po0.0001), freedom of salvage treatment (0.53 (0.40--0.71), Po0.0001), distant failure (0.67 (0.45--0.99), P ¼ 0.046) and PC-specific survival (0.56 (0.32--0.98), P ¼ 0.04). 17 The results from two large studies on hormone-refractory PC indicate that docetaxel is effective in the treatment of symptomatic hormone-refractory PC. 18, 19 Phase II trials using neoadjuvant docetaxel alone or in combination have shown significant decreases in PSA levels. 20--23 In addition, docetaxel has shown a significant survival benefit in two large studies in patients with early node-positive breast cancer. 24, 25 As docetaxel has proven to be effective in late stages of PC with a large tumor burden, it may be effective in treating intermediateand high-risk PC as an adjuvant treatment after radiotherapy to prevent relapses. Therefore, we conducted a randomized phase III trial in which patients will be randomized either to docetaxel or surveillance. This is one of the first randomized prospective phase III trials with adjuvant docetaxel after radical radiotherapy (RT) in intermediate or high-risk PC; therefore, this preplanned safety analysis was conducted.
MATERIALS AND METHODS
The inclusion criteria in the SPCG trial-13 are the following: men 418 and p75 years of age, WHO/ECOG performance status 0--1, histologically proven adenocarcinoma of the prostate within 12 months before randomization and one of the following---T2 with Gleason 7 (4 þ 3), PSA 410; T2 with Gleason 8--10, any PSA; or any T3 tumors. Prior neoadjuvant hormone therapy is mandatory for all patients, and adequate hematological, liver and kidney functions were required. The exclusion criteria are metastatic or node-positive cancer, a history of previous malignant disease (except basal or squamous cell carcinoma of the skin or curatively treated malignant disease, disease free 45 years), previous radiotherapy to the pelvic region, previous chemotherapy within 5 years, systemic corticosteroids or unstable cardiovascular disease within 6 months or active untreated infection. All patients provided written informed consent. The national ethics committees approved the trial. This study identifier number is NTC 006653848 (http://www.clinicaltrials.org).
The primary end point of the trial is PSA progression (defined according to the ASTRO-RTOG guidelines 9 ), and secondary end points are PSA doubling time, Quality of Life (FACT-P), safety (NCI-CTAE 4.0), metastasisfree survival and overall survival.
To 
RESULTS
The baseline characteristics of the 100 patients were well balanced ( Table 1 ). The mean age was 65 and 66 years, ECOG was (0/1, %) 90/10 and 90/10, the time from diagnosis was 262 and 270 days, the GS (6--7/8--10, %) was 60/40 and 44/56 and the tumor stage (T2/T3, %) was 26/74 and 28/72 in the docetaxel and control groups, respectively. The mean PSA of the 100 patients at the time of diagnosis was 21.9 ng ml
À1
, and the nadir PSA after radiotherapy was 0.25 ng ml À1 . During docetaxel treatments, G 3 adverse effects (AEs) occurred in 15 patients (30%), and G 4 AEs occurred in 29 patients (58%), mainly owing to bone marrow toxicity. Neutropenia grades 3--4 occurred in 76% of the patients: 72% after the first cycle and only 0--5% in the subsequent cycles. Febrile neutropenia was observed in 24% of the patients. Non-hematological G 3 toxicities were rare: anorexia (1 patient), diarrhea (3 patients), fatigue (3 patients), mucositis (1 patient), nausea (1 patient) and pain (1 patient). Other severe AEs related to docetaxel included infections without neutropenia and pulmonary embolism ( Table 2 ). Only three patients halted treatment owing to the toxicity of the study drug. No patients in the surveillance arm experienced G 3 or 4 toxicities at 12 weeks after the randomization. No deaths have occurred owing to the experimental treatment.
DISCUSSION
Adjuvant chemotherapy with taxane-based combinations has been shown to increase the survival in early breast cancer, and these regimens have been commonly used over the past 10 years for the treatment of intermediate-or high-grade breast cancer. 23, 24 After trials showed docetaxel activity in advanced hormone-refractory PC, 18, 19 several neoadjuvant or adjuvant control trials with docetaxel in combination with either prostatectomy or radical external radiotherapy were introduced (Table 3) in high-or intermediate-risk PC. SPCG initiated two prospective randomized trials, SPCG-12 and SPCG-13, approximately 5 years ago. In SPCG-12, six cycles of adjuvant docetaxel are given after radical prostatectomy; its enrollment is now closed after recruiting 459 patients. The SPCG-13 is an adjuvant trial after RT comparing six cycles of docetaxel combined with neoadjuvant and adjuvant hormonal treatment after radical external radiotherapy. Through December 2011, 331 patients out of the goal of 378 have been enrolled in the trial. The preplanned safety analysis reported here showed a high level of hematological toxicity. However, the Linked with adjuvant docetaxel þ hormonal treatment P-L Kellokumpu-Lehtinen et al toxicity was not associated with a discontinuation of the planned six cycles. Fewer G 3--4 toxicities were evident in the SPCG-12 study. The use of colony-stimulating growth factors (CSFs) are allowed on clinical bases, even prophylactically, under the EORTC and ASCO guidelines. 26 These new guidelines consider patient age (over 65) and comorbidities in addition to the type of chemotherapy used (Table 4) .
Before this safety analysis, colony-stimulating growth factors were mostly used after the first neutropenic episode, not prophylactically. In the final trial analysis, the use of colonystimulating growth factors would be reported and the costs analyzed. In addition, testosterone level is recorded in both groups at the time of randomization and in the follow-up phase. At the start of docetaxel treatment, all patients' testosterone values were at castration level using luteinizing hormonereleasing hormone analogs. Thus, the high incidence of neutropenia might not be explained by the longer clearance of docetaxel as was reported with non-castrated patients in a small phase II trial published by Rathkopf and collaborators. 27 On the other hand, toxicity was also very high in the preliminary toxicity analysis of RTOG 99--02 trial; 28 even two G 5 complications related to neutropenic infection accrued in the this study where paclitaxel, estramustine and oral etoposide regimen was used combined with long-term androgen suppression and radiotherapy. In addition, radiotherapy to the pelvic region might add to the hematopoietic toxicity of chemotherapy. The neoadjuvant chemotherapy might be an option and should be tested in randomized trials with radiotherapy.
In the phase III trials of advanced castration-resistant PC treated with docetaxel, G 3--4 neutropenia was reported to be 32% with docetaxel alone every 3 weeks 19 and 16% with docetaxel plus estramustine. 18 However, only 3% of febrile neutropenia was reported in the TAX 327 trial. 19 These figures are much lower than those in this SPCG-13 trial and in the RTOG 99--02 adjuvant trial. 28 In our analysis, the high amount of G 3--4 neutropenia occurred after the first docetaxel cycle (72%) and the numbers were lower in subsequent cycles (3--22%). Thus, also most of the infections or febrile neutropenia were reported after the first cycle (36% versus 0--8%).
The same principle of targeting micrometastases is applied today for the treatment of early PC in several ongoing clinical randomized trials (Table 3) . Because the mean age of PC patients is quite high, it is very important to analyze treatment safety. In an adjuvant--docetaxel trial performed by a Finnish breast cancer group, treatment-related deaths occurred. 24 In addition, another Finnish adjuvant trial had the dose of docetaxel decreased from 100 mg m À2 to 80 mg m À2 owing to a high rate of neutropenic infections. 25 Thus far, (after 331 patients) no treatment-related deaths have occurred in the SPCG-13 trial, and most of the patients included in this safety analysis have completed all six cycles of chemotherapy.
In a recent meta-analysis of 3424 PC patients, hormone suppression significantly increased both biochemical and clinical progression-free survival. 16 The current practice is to add neoadjuvant and adjuvant androgen deprivation to radiotherapy, 29 as in this study. It is very important to consider the long-term side effects of androgen deprivation. 30, 31 This is the reason why only Abbreviations: AD, androgen deprivation; ADT, androgen deprivation therapy; LT, local treatment; either prostatectomy or radiotherapy; RT, radical radiotherapy.
Linked with adjuvant docetaxel þ hormonal treatment P-L Kellokumpu-Lehtinen et al 9 months of luteinizing hormone-releasing hormone therapy is used in this SPCG-13 trial. Even following 6 months of hormone therapy, the median time for testosterone levels to return to baseline have shown to vary from 13 to 19 months depending on age. 32 The use of highly developed treatment planning is also important to avoid side effects and to deliver high doses of radiation to the tumor. 33, 34 For this reason, the three-dimensional conformal radiotherapy planning was mandatory in this trial. This safety analysis demonstrated that patients should be carefully monitored when chemotherapy is combined with prostate radiotherapy, and hematopoietic growth factors should be used liberally according to the clinical guidelines (Table 4) .
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Secondary prophylaxis
After a neutropenic complication from a prior cycle of chemotherapy (for which primary prophylaxis is not used), in which reduced dose may comprise disease or overall survival
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